ACMPR Applicant TerrAscend to Debut on CSE on May 3rd

Visit the TerrAscend Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.

Terrascend

TerrAscend Announces Approval for Listing on the Canadian Securities Exchange and Stock Option Grant

TORONTO, ONTARIO–(Marketwired – May 2, 2017) –

TerrAscend Corp. (CSE: TER) (“TerrAscend” or the “Company”), is pleased to announce that the Company’s common shares (“Common Shares”) have been approved for listing on the Canadian Securities Exchange (“CSE”) under the symbol ‘TER’. Pursuant to the CSE bulletin dated May 2, 2017, the Common Shares will commence trading on the CSE at market open on May 3, 2017.

The listing of the Company’s Common Shares on the CSE is an important milestone in the development of the Company and towards achieving our goal of becoming a leading provider of medical cannabis. We have the infrastructure and key personnel in place to provide shareholders with a unique value proposition.

Basem HannaBasem Hanna, Co-founder and Chief Executive Officer

TerrAscend is focused on the production, sale and distribution of cannabis and its derivatives for the medical market. The Company’s wholly-owned subsidiary, Solace Health Inc. is in the final stage of its application for licencing under the Access to Cannabis for Medical Purposes Regulations. TerrAscend has an experienced management team and Board of Directors with expertise in pharmaceutical production, cannabis cultivation and a deep-rooted network of healthcare professionals.

Solace operates a wholly owned, 67,300 square foot production facility in Mississauga, Ontario, with a distinct geographic distribution advantage being proximate to Pearson International Airport and seven major transportation arteries. Upon completion of the final build-out of the production facility, management anticipates the total annual production capacity to exceed 6,000kgs of dried product per year with over 9,500 sq. ft. dedicated to research and development.

Stock Option Grant

The Company has today issued options to certain directors, officers and consultants of the Company to purchase an aggregate of 1,450,000 Common Shares at an exercise price of $0.60 for a period expiring 10 years from the issue date. 100,000 options vest immediately, 350,000 vest upon listing of the Common Shares on the CSE, 300,000 vest on March 7, 2018 and the balance vest on upon the achievement of certain predetermined corporate milestones. The stock options are being granted pursuant to the terms of the Company’s stock option plan.

About TerrAscend

Based in Mississauga, ON, TerrAscend is a vertically integrated Canadian Cannabis company that strives to create and deliver quality products and services that meet the evolving needs of the medical cannabis market. TerrAscend’s wholly-owned subsidiary, Solace Health Inc., is in the final stage of its application for licensing under Access to Cannabis for Medical Purposes Regulations.

Original press release: http://www.marketwired.com/press-release/-2213597.htm

For fact-based information on TerrAscend, view the company’s sponsored Investor Dashboard.

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter